Clinical diagnostics company BioChain has licensed Epigenomics' methylated Septin9 marker, designed for the blood based detection of colorectal cancer (CRC).
Under the license, BioChain will offer Septin9 assay as a service to customers through its Beijing-based Chinese independent reference laboratory.
BioChain Institute chief executive officer Grace Tian said, "Through this agreement we will immediately initiate efforts in China to validate and deploy the methylated Septin9 assay allowing the establishment of new standards for access and convenience in our home market."
Epigenomics chief financial officer and acting chief executive officer Thomas Taapken said the company is pleased that BioChain has decided to make a methylated Septin9 assay available in mainland China.
"This allows more convenient alternatives for CRC screening to become available in this emerging market, where prevalence of CRC in the population is on the raise and growing awareness is creating a need for early detection," Taapken added.
